Prostatype Genomics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Prostatype Genomics şirketinin toplam hissedar öz sermayesi SEK13.3M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK32.3M ve SEK19.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 1.79m
Eşitlik	SEK 13.29m
Toplam yükümlülükler	SEK 18.99m
Toplam varlıklar	SEK 32.27m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PGO 'nin kısa vadeli varlıkları ( SEK3.2M ) kısa vadeli yükümlülüklerini ( SEK19.0M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: PGO un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PGO borçsuzdur.

Borcun Azaltılması: PGO şirketinin 5 yıl önce borç/öz sermaye oranı 80.2% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PGO şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: PGO un, serbest nakit akışı her yıl % 26.4 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Prostatype Genomics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Independent Director recently bought €72k worth of stock

Prostatype Genomics AB (publ) has completed a Composite Units Offering in the amount of SEK 39.535402 million.

First half 2024 earnings released: kr0.031 loss per share (vs kr0.37 loss in 1H 2023)

Prostatype Genomics AB (Publ) Elects Johan Waldhe as New Member of the Board

Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala

Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®

Prostatype Genomics AB (publ) to Report Fiscal Year 2024 Results on Feb 13, 2025

Full year 2023 earnings released

Prostatype Genomics AB (publ) Announces Long Term Follow Up Study At Akademiska University Hospital, Uppsala, to Be Presented At EAU-Meeting, May 2024: Indicates New Area of Use for Prostatype®

Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors Prematurely

Prostatype Genomics Appoints Anders Koch as New CFO

Prostatype Genomics AB (Publ) Announces Updated Strategy and Implementation of Efficiency Programs in Prostatype Genomics

Prostatype Genomics Announces New Multi-Centre Study in Spain Shows Very Strong Interim Results for Prostatype(R)

Forecast to breakeven in 2025

Prostatype Genomics CFO Michael af Winklerfelt Leaving the Company

Forecast to breakeven in 2025

Second quarter 2023 earnings released

Prostatype Genomics AB (Publ) Provides Revenue Guidance for the Third Quarter of 2023

Now 22% undervalued after recent price drop

Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical Officer

First quarter 2023 earnings released

Prostatype Genomics AB (Publ) Announces Executive Changes

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.

Prostatype Genomics AB Appoints Professor Gerald Andriole as Chief Medical Officer

Full year 2022 earnings released: kr1.27 loss per share (vs kr1.11 loss in FY 2021)

Prostatype Genomics AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023

Prostatype Genomics AB (publ) to Report Q2, 2023 Results on Aug 17, 2023

Prostatype Genomics Appoints Steven Gaal as President

Prostatype Genomics AB (Publ) Provides Sales Guidance for the Year 2022

Prostatype Genomics Announces Management Changes

Prostatype Shows Strong Data in Asian Pilot Study

Second quarter 2022 earnings released

High number of new directors

Prostatype Genomics AB (Publ) Appoints Mattias Prage as Member of the Board

First quarter 2022 earnings released

Insufficient new directors

Prostatype Genomics AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

Third quarter 2021 earnings released

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.724583 million.

Second quarter 2021 earnings released: kr0.18 loss per share (vs kr0.42 loss in 2Q 2020)

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin